FGF2-PI3K-Akt1 signaling

Overview

The FGF2-PI3K-Akt1 signaling axis refers to the intracellular cascade initiated by fibroblast growth factor 2 (FGF2) binding to its cognate receptors, leading to the activation of phosphoinositide 3-kinase (PI3K) and its downstream effector serine/threonine kinase Akt1 (also known as protein kinase B alpha). This pathway is a central regulator of cell survival, proliferation, differentiation, and metabolism across a wide range of tissue types. Upon FGF2-mediated receptor engagement, PI3K phosphorylates phosphatidylinositol lipids at the plasma membrane, generating second messengers that recruit and activate Akt1. Once activated, Akt1 phosphorylates numerous substrates involved in cell cycle progression, apoptotic suppression, and anabolic signaling, including components associated with mTOR, FOXO transcription factors, and downstream effectors such as MYC proto-oncogene (MYC) and Matrix Metalloproteinase-9 (MMP-9) (MMP9). The pathway intersects extensively with parallel cascades including MAPK/ERK, JAK-STAT, and Wnt/β-catenin signaling, making it a critical node in both normal physiology and pathological conditions such as cancer, metabolic disease, inflammatory disorders, and tissue aging.

The biological relevance of FGF2-PI3K-Akt1 signaling is underscored by its roles in stem cell maintenance and tissue homeostasis. In bone marrow, for instance, FGF2-PI3K-Akt1 activity supports the function of mesenchymal stromal cells, and its dysregulation has been implicated in age-related changes in bone marrow biology. Dysactivation of this pathway—whether through upstream receptor tyrosine kinase mutations, ligand overexpression, or loss of negative regulators such as PTEN—contributes to oncogenesis and treatment resistance, motivating considerable drug discovery efforts targeting PI3K, Akt1, and associated kinases including FGFR1.

Recent Publications Summary

Recent publications have continued to implicate PI3K/Akt-related signaling as a recurrent mechanistic axis in studies where FGF2-PI3K-Akt1 signaling was examined as a target, particularly in cancer and metabolic disease contexts. In breast cancer, an in silico screening study of Scutellaria barbata identified apigenin, 4'-hydroxywogonin, and hispidulin as bioactive flavonoids with favorable drug-like properties; network analysis highlighted AKT1 as a central hub enriched in the PI3K-Akt pathway, and molecular docking showed strong binding of these compounds to hub proteins 42348584Jun. Similarly, a multi-omics toxicology study in lung adenocarcinoma identified AKT1 among six hub toxicological targets linked to PFAS-associated disease networks, again pointing to PI3K/Akt-centered signaling in pathogenesis 42334505Jun.

Several studies combined network pharmacology, molecular docking, and experimental validation to connect natural products with PI3K/Akt pathway modulation. In oral squamous cell carcinoma, hippeastrine from Anemarrhena asphodeloides was highlighted as a regulator of the HSP90/PI3K/Akt/mTOR axis; the compound showed stable binding to HSP90 and AKT1 in silico, and in vitro it suppressed proliferation, colony formation, migration, and invasion while promoting cytotoxicity in CAL27 and SCC-9 cells 42216572May. In glioma, scutellarein inhibited proliferation, migration, and invasion and induced apoptosis, with network pharmacology, transcriptomics, and western blotting supporting modulation of the PI3K/Akt signaling pathway 41966746Apr. Another glioblastoma study found that Aucan suppressed PI3K/AKT signaling, reduced tumor growth in mouse models, and increased apoptosis, with CDK2 identified as a key target 41846012Mar.

Additional publications linked AKT1-centered signaling to inflammatory and metabolic phenotypes. Shenling Baizhu Powder was reported to improve ulcerative colitis with spleen deficiency and dampness stagnation in rat models, and network pharmacology identified AKT1 among six core targets; docking and dynamics analyses suggested strong binding of multiple active components to these targets 42089391May. In insulin-resistant adipocytes and diet-induced obese mice, exercise-induced lactate improved insulin resistance through GPR81 and potentiated glucose uptake via the IRS1-AKT-GLUT4 pathway, underscoring AKT-dependent metabolic signaling 41989764Apr. In chronic mountain sickness, Bawei Chenxiang Wan was described as acting through the AKT/FOXO3a/CAT axis to inhibit oxidative stress, further extending AKT-linked mechanisms beyond oncology 41794256Mar.

Across these studies, AKT1 repeatedly emerged as a hub node or mechanistic mediator in pathway analyses, docking studies, and functional experiments, often alongside PI3K/Akt, MAPK, mTOR, or oxidative stress-related signaling 42348584Jun42235855Jun42216572May41966746Apr41846012Mar42089391May41989764Apr41794256Mar. Collectively, the recent literature supports continued interest in FGF2-PI3K-Akt1 signaling as a convergent pathway in cancer progression, inflammatory disease, and metabolic regulation, with natural compounds and complex herbal formulations frequently investigated as modulators of this axis 42348584Jun42216572May41966746Apr42089391May.

What Changes, What Holds

1. AKT1 remains a recurring hub in disease-network analyses, but the new work mostly extends the same signaling logic into additional cancer and toxicology settings
REINFORCES These studies do not alter the baseline account of FGF2-PI3K-Akt1 signaling as a central survival and proliferation axis; they reinforce AKT1’s repeated appearance as a network hub in PI3K/Akt-centered disease models. The main implication is breadth, not revision: the pathway continues to look broadly relevant across malignancy and exposure-related disease, but the evidence here is still largely associative and computational rather than mechanistically displacing the established model 42348584Jun42334505Jun.

2. PI3K/Akt modulation is being used as a practical anticancer readout, not a replacement for the established mechanism
REINFORCES The new studies strengthen the idea that FGF2-PI3K-Akt1-linked signaling remains a tractable therapeutic node in cancer, especially where compounds suppress proliferation, migration, invasion, and survival. Nothing here overturns the baseline description of Akt1 as a downstream effector in growth control; instead, these reports add more examples of pathway inhibition as a plausible anticancer strategy. The unresolved issue is specificity: the work supports pathway engagement, but not yet a unique causal role for FGF2 itself 42216572May41966746Apr.

3. AKT-centered signaling now appears relevant to inflammatory and metabolic phenotypes beyond the baseline’s cancer and stem-cell emphasis
NEW DIRECTION The Overview covers cancer, metabolism, inflammation, and tissue aging in general terms, but not these specific disease contexts or the therapeutic framing used here. These findings extend the entity into ulcerative colitis, insulin resistance, and chronic mountain sickness, where AKT-linked nodes are presented as mediators of benefit and stress adaptation. That broadens the map of where the axis may matter, while leaving the core FGF2-PI3K-Akt1 mechanism intact 42089391May41989764Apr41794256Mar.

4. Recent literature keeps converging on AKT1 as a shared mechanistic node across disparate models, but it does not yet resolve whether that convergence is causal or merely recurrent
REINFORCES Across the cited studies, AKT1 repeatedly functions as the common denominator in pathway and docking analyses, which is consistent with the baseline’s view of Akt1 as a central downstream effector. What changes is confidence in its ubiquity, not the direction of the biology. The remaining gap is translational: repeated network prominence does not by itself prove that FGF2-driven PI3K-Akt1 signaling is the decisive driver in each setting 42348584Jun42235855Jun42216572May41966746Apr41846012Mar42089391May41989764Apr41794256Mar.

Overview update candidates: AKT1-centered signaling in ulcerative colitis; insulin resistance; and chronic mountain sickness; continued cross-disease convergence on AKT1 as a hub node.